|
Upcoming Lectures |
|
There are no events to display. |
Recent Lectures |
Tuesday, 4/14/09 7:30pm | | AB Lectures Presents: Sudhir Venkatesh | | AB Lectures Presents: Sudhir Venkatesh
Author of "Gang Leader For A Day" and "American Projects" -- Featured in
"Freakonomics" -- Professor at Columbia University
CMU Porter Hall 100 -- April 14, 2009 at 7:30pm -- Admission is Free
Sudhir Venkatesh is William B. Ransford Professor of Sociology at Columbia
University in the City of New York. He is a researcher and writer on urban
neighborhoods in the United States (New York, Chicago) and Paris, France. He is also
a documentary film-maker. His most recent book is Gang Leader for a Day (Penguin
Press). First presented in Freakonomics, the story of a young sociologist who
embedded himself in Chicago’s most notorious gang and captured the world’s
attention. Gang Leader for a Day is the fascinating full story of how Sudhir
Venkatesh gained entrance into the lives of a group of drug-dealers and went on to
witness—and participate in—events that have rarely been described in print. A
brazen, page-turning, and fundamentally honest view of the morally ambiguous, highly
intricate, often corrupt struggle to survive in an urban war zone, it is also an
emotional and complicated look at the friendship that develops between the
sociologist and a gang leader, two ambitious men a universe apart.
Venkatesh has produced several documentaries. The documentary film, Dislocation,
follows families as they relocate from condemned public housing developments. The
documentary aired on PBS in 2005. He directed and produced a three-part award
winning documentary on the history of public housing for NPR. He is currently
completing a documentary film on scholars and artists at-risk around the globe.
Venkatesh received his Ph.D. in Sociology from the University of Chicago. He was a
Junior Fellow at the Society of Fellows, Harvard University from 1996-1999. He is
currently Director of the Center for Urban Research and Policy, and Director of the
Charles H. Revson Fellowship Program, both at Columbia University.
| More... | | | Wednesday, 3/4 5pm | | Anna Deavere Smith | |
NOTE**** ACTUALLY IN CHOSKY THEATRE in Purnell!
Anna Deavere Smith is a Pulitzer Prize Nominated Playwright. She is also a MacArthur Fellow (the "Genius Award"), a two-time Tony Award Nominee, and a two-time Drama Desk Award Winner. Anna can be seen acting in shows such as The West Wing and The Practice and films such as Philadelphia, and The American President. Most Notably, Anna is famous for her work as a playwright. She is the writer of "Fires in the Mirror", "Twilight: Los Angeles 1992", "Let Me Down Easy", and many more. Please join us on Wednesday, March 4 at 5pm for a lecture in the Philip Chosky Theatre followed by a reception in the lobby outside of the theatre.
| More... | | | Thursday, (2,15) 5pm | | Aubrey de Grey - "Prospects for defeating aging altogether" | | Dr. Aubrey de Grey is a biomedical gerontologist based in Cambridge, UK, and is the Chairman and Chief Science Officer of the Methuselah Foundation, a 501(c)(3) non-profit charity dedicated to combating the aging process. His research interests encompass the etiology of all the accumulating and eventually pathogenic molecular and cellular side-effects of metabolism ("damage") that constitute mammalian aging and the design of interventions to repair and/or obviate that damage. He has developed a possibly comprehensive plan for such repair, termed Strategies for Engineered Negligible Senescence (SENS), which breaks the aging problem down into seven major classes of damage and identifies detailed approaches to addressing each one. de Grey has termed this required rate of improvement of repair therapies "longevity escape velocity". In his talk he will explain, first, why (presuming adequate funding for the initial preclinical work) therapies that can add 30 healthy years to the ! remaining lifespan of healthy 60-year-olds may well arrive within the next few decades, and, second, why those who benefit from those therapies will very probably continue to benefit from progressively improved therapies indefinitely and thus avoid debilitation or death from age-related causes at any age. | More... | | | |
|
|